https://waldenbiosciences.com/walden-biosciences-launches-to-transform-the-treatment-of-kidney-disease/ 2024-07-25T14:40:24+00:00 https://waldenbiosciences.com/walden-biosciences-announces-participation-at-4th-annual-chronic-kidney-disease-drug-development-ckd-summit/ 2024-08-07T14:51:34+00:00 https://waldenbiosciences.com/walden-biosciences-announces-presentation-at-the-32nd-annual-oppenheimer-healthcare-conference/ 2024-08-07T14:52:30+00:00 https://waldenbiosciences.com/walden-biosciences-to-participate-in-june-investor-conferences/ 2024-08-07T14:53:36+00:00 https://waldenbiosciences.com/walden-biosciences-announces-research-collaboration-with-university-of-michigan/ 2024-08-07T14:58:46+00:00 https://waldenbiosciences.com/walden-biosciences-announces-presentation-at-canaccord-genuity-42nd-annual-growth-conference/ 2024-08-07T14:59:09+00:00 https://waldenbiosciences.com/walden-biosciences-announces-virtual-presentation-at-canaccord-genuity-41st-annual-growth-conference/ 2024-08-07T15:00:16+00:00 https://waldenbiosciences.com/walden-biosciences-announces-participation-in-citis-17th-annual-biopharma-conference/ 2024-08-07T15:01:54+00:00 https://waldenbiosciences.com/walden-biosciences-appoints-peter-guest-linde-m-d-as-chief-medical-officer/ 2024-08-07T15:02:47+00:00 https://waldenbiosciences.com/walden-biosciences-announces-participation-at-october-investor-conferences/ 2024-08-07T15:03:28+00:00 https://waldenbiosciences.com/walden-biosciences-announces-presentation-at-antibody-engineering-and-therapeutics-conference-2022/ 2024-08-07T15:04:18+00:00 https://waldenbiosciences.com/walden-biosciences-to-present-at-5th-annual-chronic-kidney-disease-drug-development-summit/ 2024-08-07T15:05:04+00:00 https://waldenbiosciences.com/walden-biosciences-announces-presentation-at-the-oppenheimer-33rd-annual-healthcare-conference/ 2024-08-07T15:05:43+00:00 https://waldenbiosciences.com/walden-biosciences-promotes-curt-dewan-cfa-to-chief-financial-officer/ 2024-08-07T15:06:35+00:00 https://waldenbiosciences.com/walden-biosciences-announces-first-subject-dosed-in-first-in-humans-phase-1-clinical-trial-of-wal0921-in-development-for-treatment-of-chronic-kidney-diseases/ 2024-08-07T15:07:19+00:00 https://waldenbiosciences.com/walden-biosciences-to-host-virtual-event-on-november-14-2023-transforming-the-treatment-landscape-of-chronic-kidney-disease/ 2024-08-07T15:07:55+00:00 https://waldenbiosciences.com/walden-biosciences-expands-research-collaboration-with-the-university-of-michigan/ 2024-08-07T15:08:55+00:00 https://waldenbiosciences.com/walden-biosciences-announces-positive-topline-data-from-phase-1-clinical-study-of-wal0921-in-development-for-treatment-of-kidney-diseases/ 2024-08-07T15:09:41+00:00 https://waldenbiosciences.com/walden-biosciences-announces-research-collaboration-with-world-renowned-genetic-epidemiologist-to-advance-work-on-causal-role-of-supar-in-chronic-kidney-disease/ 2024-08-07T15:10:30+00:00 https://waldenbiosciences.com/select-supar-references/ 2024-08-08T14:17:39+00:00 https://waldenbiosciences.com/select-dynamin-references/ 2024-08-08T14:17:50+00:00 https://waldenbiosciences.com/walden-biosciences-fully-enrolls-first-cohort-in-phase-2-basket-study-of-wal0921-in-chronic-kidney-diseases/ 2025-01-02T15:55:02+00:00 https://waldenbiosciences.com/walden-biosciences-highlights-2024-accomplishments-and-2025-priorities/ 2025-01-10T15:12:57+00:00 https://waldenbiosciences.com/walden-biosciences-appoints-howard-mayer-m-d-to-board-of-directors/ 2025-01-28T18:36:20+00:00 https://waldenbiosciences.com/walden-biosciences-announces-key-initiatives-to-advance-clinical-pipeline-and-support-phase-2-program-for-wal0921-in-rare-kidney-diseases/ 2025-09-04T12:16:45+00:00 https://waldenbiosciences.com/walden-biosciences-to-participate-in-24th-annual-morgan-stanley-global-healthcare-conference/ 2026-10-02T12:55:38+00:00 https://waldenbiosciences.com/walden-biosciences-announces-cmo-appointment-and-upcoming-clinical-data-for-wal0921-in-proteinuric-chronic-kidney-disease/ 2026-10-02T12:55:45+00:00 https://waldenbiosciences.com/walden-biosciences-to-present-phase-1-and-phase-2-data-for-wal0921-at-american-society-of-nephrology-kidney-week/ 2026-10-19T20:44:00+00:00 https://waldenbiosciences.com/walden-biosciences-announces-positive-data-from-diabetic-kidney-disease-cohorts-in-ongoing-phase-2-study-of-wal0921/ 2026-10-22T16:00:30+00:00